{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:40:40Z","timestamp":1779316840165,"version":"3.51.4"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T00:00:00Z","timestamp":1647907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the CAMS Innovation Fund for Medical Sciences","award":["CIFMS, 2017-I2M-3-001"],"award-info":[{"award-number":["CIFMS, 2017-I2M-3-001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00330-022-08624-7","type":"journal-article","created":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T06:02:50Z","timestamp":1647928970000},"page":"5568-5576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Baseline [18F]FDG PET\/CT may predict the outcome of newly diagnosed follicular lymphoma in patients managed with initial \u201cwatch-and-wait\u201d approach"],"prefix":"10.1007","volume":"32","author":[{"given":"Qiao","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5787-1136","authenticated-orcid":false,"given":"Yaping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,22]]},"reference":[{"key":"8624_CR1","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/ajh.25696","volume":"95","author":"A Freedman","year":"2020","unstructured":"Freedman A, Jacobsen E (2020) Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol 95:316\u2013327","journal-title":"Am J Hematol"},{"key":"8624_CR2","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/leu.2014.91","volume":"28","author":"W Hiddemann","year":"2014","unstructured":"Hiddemann W, Cheson BD (2014) How we manage follicular lymphoma. Leukemia 28:1388\u20131395","journal-title":"Leukemia"},{"key":"8624_CR3","doi-asserted-by":"publisher","unstructured":"Dreyling M, Ghielmini M, Rule S et al (2020) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.008","DOI":"10.1016\/j.annonc.2020.11.008"},{"key":"8624_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/RLU.0000000000002457","volume":"44","author":"Q Pan","year":"2019","unstructured":"Pan Q, Luo Y, Cao X, Zhang Y, Li F (2019) Spontaneous regression of clinically indolent lymphomas revealed by [18F]FDG PET\/CT. Clin Nucl Med 44:321\u2013323","journal-title":"Clin Nucl Med"},{"key":"8624_CR5","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1097\/MNM.0000000000001279","volume":"41","author":"Y Luo","year":"2020","unstructured":"Luo Y, Zhang Y, Pan Q, Zhang Y, Li F (2020) [18F]FDG PET\/computed tomography may predict the outcome of newly diagnosed indolent non-Hodgkin lymphoma in patients managed with initial 'watch-and-wait' approach. Nucl Med Commun 41:1283\u20131290","journal-title":"Nucl Med Commun"},{"key":"8624_CR6","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2015-11-632745","volume":"127","author":"JO Armitage","year":"2016","unstructured":"Armitage JO, Longo DL (2016) Is watch and wait still acceptable for patients with low-grade follicular lymphoma? Blood 127:2804\u20132808","journal-title":"Blood"},{"key":"8624_CR7","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A et al (2003) Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362:516\u2013522","journal-title":"Lancet"},{"key":"8624_CR8","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1200\/JCO.2004.10.086","volume":"22","author":"R Advani","year":"2004","unstructured":"Advani R, Rosenberg SA, Horning SJ (2004) Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol 22:1454\u20131459","journal-title":"J Clin Oncol"},{"key":"8624_CR9","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","volume":"30","author":"P Solal-C\u00e9ligny","year":"2012","unstructured":"Solal-C\u00e9ligny P, Bellei M, Marcheselli L et al (2012) Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol 30:3848\u20133853","journal-title":"J Clin Oncol"},{"key":"8624_CR10","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/bjh.13895","volume":"172","author":"LJ Nastoupil","year":"2016","unstructured":"Nastoupil LJ, Sinha R, Byrtek M et al (2016) Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. Br J Haematol 172:724\u2013734","journal-title":"Br J Haematol"},{"key":"8624_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","volume":"15","author":"KM Ardeshna","year":"2014","unstructured":"Ardeshna KM, Qian W, Smith P et al (2014) Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol 15:424\u2013435","journal-title":"Lancet Oncol"},{"key":"8624_CR12","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S1470-2045(14)70066-X","volume":"15","author":"SM Ansell","year":"2014","unstructured":"Ansell SM (2014) Follicular lymphoma: watch and wait is watch and worry. Lancet Oncol 15:368\u2013369","journal-title":"Lancet Oncol"},{"key":"8624_CR13","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S1470-2045(14)70215-3","volume":"15","author":"T LeBlanc","year":"2014","unstructured":"LeBlanc T, Kamal A, Abernethy A (2014) Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live? Lancet Oncol 15:e251\u2013e252","journal-title":"Lancet Oncol"},{"key":"8624_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00277-017-3154-z","volume":"97","author":"M Sorigue","year":"2018","unstructured":"Sorigue M, Sancho JM (2018) Current prognostic and predictive factors in follicular lymphoma. Ann Hematol 97:209\u2013227","journal-title":"Ann Hematol"},{"key":"8624_CR15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/bjh.13316","volume":"169","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC, Bilgrau AE, de Nully BP et al (2015) A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. Br J Haematol 169:435\u2013444","journal-title":"Br J Haematol"},{"key":"8624_CR16","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068","journal-title":"J Clin Oncol"},{"key":"8624_CR17","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00259-012-2079-y","volume":"39","author":"E Lopci","year":"2012","unstructured":"Lopci E, Zanoni L, Chiti A et al (2012) FDG PET\/CT predictive role in follicular lymphoma. Eur J Nucl Med Mol Imaging 39:864\u2013871","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8624_CR18","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A et al (2016) Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol 34:3618\u20133626","journal-title":"J Clin Oncol"},{"key":"8624_CR19","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.3324\/haematol.2019.230649","volume":"105","author":"P Strati","year":"2020","unstructured":"Strati P, Ahmed MA, Fowler NH et al (2020) Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma. Haematologica 105:1907\u20131913","journal-title":"Haematologica"},{"key":"8624_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/j.1365-2141.2011.08969.x","volume":"156","author":"C McNamara","year":"2012","unstructured":"McNamara C, Davies J, Dyer M et al (2012) Guidelines on the investigation and management of follicular lymphoma. Br J Haematol 156:446\u2013467","journal-title":"Br J Haematol"},{"key":"8624_CR21","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ajh.23372","volume":"88","author":"PL Zinzani","year":"2013","unstructured":"Zinzani PL, Marchetti M, Billio A et al (2013) SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma. Am J Hematol 88:185\u2013192","journal-title":"Am J Hematol"},{"key":"8624_CR22","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/annonc\/mds517","volume":"24","author":"M Ghielmini","year":"2013","unstructured":"Ghielmini M, Vitolo U, Kimby E et al (2013) ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol 24:561\u2013576","journal-title":"Ann Oncol"},{"key":"8624_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clml.2014.07.015","volume":"15","author":"J Kuruvilla","year":"2015","unstructured":"Kuruvilla J, Assouline S, Hodgson D et al (2015) A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board. Clin Lymphoma Myeloma Leuk 15:59\u201374","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"8624_CR24","doi-asserted-by":"publisher","first-page":"650","DOI":"10.6004\/jnccn.2019.0029","volume":"17","author":"AD Zelenetz","year":"2019","unstructured":"Zelenetz AD, Gordon LI, Abramson JS et al (2019) NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw 17:650\u2013661","journal-title":"J Natl Compr Canc Netw"},{"key":"8624_CR25","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/bjh.13316","volume":"169","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC, Bilgrau AE, de Nully BP et al (2015) A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. Br J Haematol 169:435\u2013444","journal-title":"Br J Haematol"},{"key":"8624_CR26","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:3048\u20133058","journal-title":"J Clin Oncol"},{"key":"8624_CR27","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33:2516\u20132522","journal-title":"J Clin Oncol"},{"key":"8624_CR28","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","volume":"30","author":"JW Friedberg","year":"2012","unstructured":"Friedberg JW, Byrtek M, Link BK et al (2012) Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol 30:3368\u20133375","journal-title":"J Clin Oncol"},{"key":"8624_CR29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/bjh.16011","volume":"186","author":"C Casulo","year":"2019","unstructured":"Casulo C (2019) How I manage patients with follicular lymphoma. Br J Haematol 186:513\u2013523","journal-title":"Br J Haematol"},{"key":"8624_CR30","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-C\u00e9ligny","year":"2004","unstructured":"Solal-C\u00e9ligny P, Roy P, Colombat P et al (2004) Follicular lymphoma international prognostic index. Blood 104:1258\u20131265","journal-title":"Blood"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-08624-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-022-08624-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-08624-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T21:45:12Z","timestamp":1657748712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-022-08624-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,22]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["8624"],"URL":"https:\/\/doi.org\/10.1007\/s00330-022-08624-7","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,22]]},"assertion":[{"value":"5 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Yaping Luo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Some study subjects or cohorts have been previously reported in:Clin Nucl Med. 2019 Apr;44(4):321-323.Nucl Med Commun 41:1283-1290We reported one case of follicular lymphoma (FL) with spontaneous regression during \u201cwatch-an-wait\u201d period revealed by <sup>18<\/sup>F-FDG PET\/CT as an Interesting Image in Clinical Nuclear Medicine. Then we reported 16 patients with indolent NHL (including 9 patients with FL) treated with initial watchful waiting as an Original Article in Nuclear Medicine Communications. These patients all had baseline and at least one follow-up <sup>18<\/sup>F-FDG PET\/CT scan. In the follow-up PET\/CT, it was revealed that 4 out of 16 patients showed spontaneous regression of NHL lesions. In univariate analysis, MTV and TLG in baseline PET\/CT were significant predictors for early treatment of indolent NHL under watchful waiting. However, the small sample size and heterogeneity of lymphoma types limited the statistical power. Therefore, in the current study, we selected a single indolent lymphoma type, increased the sample size, and focused on the role of baseline <sup>18<\/sup>F-FDG PET\/CT to predict the outcome of FL in patients managed with an initial \u201cwatch-and-wait\u201d approach.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"value":"\u2022 retrospective\u2022 diagnostic or prognostic study\/observational\u2022 performed at one institution","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}